Structure Therapeutics (NASDAQ:GPCR) Hits New 52-Week Low – Should You Sell?

Structure Therapeutics Inc. Sponsored ADR (NASDAQ:GPCR) shares reached a new 52-week low during mid-day trading on Wednesday. The company traded as low as $22.10 and last traded at $22.31, with a volume of 1,434,790 shares changing hands. The stock had previously closed at $23.91.

Analysts Set New Price Targets

A number of brokerages have recently commented on GPCR. Wall Street Zen lowered Structure Therapeutics from a “sell” rating to a “strong sell” rating in a report on Saturday, October 3rd. Weiss Ratings raised Structure Therapeutics from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Tuesday, October 6th. Citigroup restated a “market outperform” rating on shares of Structure Therapeutics in a research note on Friday, August 7th. Citizens Jmp reaffirmed a “market outperform” rating and set a $110.00 target price on shares of Structure Therapeutics in a research report on Wednesday, September 9th. Finally, HC Wainwright reiterated a “buy” rating on shares of Structure Therapeutics in a research note on Wednesday, September 9th. Two research analysts have rated the stock with a Strong Buy rating, twelve have issued a Buy rating, one has assigned a Hold rating and two have assigned a Sell rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $110.91.

Structure Therapeutics Stock Down 6.7%

The company’s fifty day simple moving average is $41.47 and its 200-day simple moving average is $44.50.

Structure Therapeutics (NASDAQ:GPCR) last announced its quarterly earnings data on Thursday, August 6th. The company reported ($0.49) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.39) by ($0.10). On average, equities research analysts forecast that Structure Therapeutics Inc. Sponsored ADR will post -1.87 earnings per share for the current fiscal year.

Institutional Trading of Structure Therapeutics

A number of institutional investors and hedge funds have recently added to or reduced their stakes in GPCR. IFP Advisors Inc acquired a new position in Structure Therapeutics in the second quarter worth about $46,000. Squarepoint Ops LLC boosted its holdings in Structure Therapeutics by 454.5% during the second quarter. Squarepoint Ops LLC now owns 125,575 shares of the company’s stock valued at $6,740,000 after purchasing an additional 102,929 shares in the last quarter. Seven Fleet Capital Management LP boosted its holdings in Structure Therapeutics by 197.8% during the second quarter. Seven Fleet Capital Management LP now owns 26,800 shares of the company’s stock valued at $1,442,000 after purchasing an additional 17,800 shares in the last quarter. Wellington Management Group LLP grew its stake in shares of Structure Therapeutics by 1.6% in the 2nd quarter. Wellington Management Group LLP now owns 7,379,433 shares of the company’s stock valued at $396,054,000 after purchasing an additional 119,146 shares during the period. Finally, Handelsbanken Fonder AB bought a new stake in shares of Structure Therapeutics in the 2nd quarter valued at approximately $1,041,000. Institutional investors own 91.78% of the company’s stock.

About Structure Therapeutics

Structure Therapeutics Inc is a clinical-stage biopharmaceutical company developing oral small-molecule medicines for chronic metabolic and cardiopulmonary diseases. The company uses structure-based drug discovery and related technologies to identify therapies intended to address conditions with significant unmet medical needs.

Its lead product candidate is GSBR-1290, an investigational oral small-molecule agonist of the glucagon-like peptide-1 (GLP-1) receptor being developed for obesity and type 2 diabetes.